Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A known ✓ | P08908 | 9/20 | 0.41 |
| ▸ | ADRA1A known ✓ | P35348 | 4/20 | 0.41 |
| ▸ | ADRA1D known ✓ | P25100 | 3/20 | 0.41 |
| ▸ | ADRA1B known ✓ | P35368 | 3/20 | 0.41 |
| ▸ | HTR2A known ✓ | P28223 | 5/20 | 0.38 |
| ▸ | HTR2C known ✓ | P28335 | 3/20 | 0.38 |
| ▸ | SLC6A4 known ✓ | P31645 | 2/20 | 0.38 |
| ▸ | DRD3 known ✓ | P35462 | 4/20 | 0.37 |
| ▸ | DRD2 known ✓ | P14416 | 3/20 | 0.37 |
| ▸ | HTR7 known ✓ | P34969 | 1/20 | 0.37 |
| ▸ | HTR6 known ✓ | P50406 | 1/20 | 0.37 |
| ▸ | FAAH | O00519 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5926074 | 0.99 | HTR1A (0.41) | HTR1AADRA1AADRA1DADRA1BHTR2A | |
| Hydrochloric Acid SCHEMBL5926077 | 0.85 | HTR1A (0.47) | HTR1AADRA1AADRA1DADRA1BSLC6A4 | |
| SCHEMBL5926075 | 0.84 | HTR1A (0.47) | HTR1AADRA1AADRA1DADRA1BSLC6A4 | |
| SCHEMBL27263980 | 0.78 | DRD2 (0.54) | HTR1AADRA1AADRA1BHTR2AHTR2C | |
| SCHEMBL5926325 | 0.77 | DRD2 (0.48) | HTR1AADRA1AADRA1DADRA1BHTR2A | |
| SCHEMBL5926097 | 0.74 | HTR7 (0.56) | HTR1AHTR2ADRD2MAPTHTR7 | |
| SCHEMBL5926079 | 0.74 | HTR1A (0.54) | HTR1AADRA1A | |
| SCHEMBL5926141 | 0.72 | KCNH2 (0.53) | HTR1AADRA1AHTR2ASLC6A4DRD3 | |
| SCHEMBL5926085 | 0.72 | PIM1 (0.47) | HTR1AHTR2AHTR2CDRD3DRD2 | |
| SCHEMBL5926252 | 0.71 | HTR2A (0.53) | HTR1AHTR2AHTR2CDRD2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060211703-A1 | Substituted alkyl-pyridazinones for the treatment of memory and learning malfunctions | EGIS GYOGYSZERGYAR RT. (HU) | 2006-09-21 | — | — | US | disclosed |
| US-20050043314-A1 | Substituted alkylaminopyridazinone derivatives, process for the preparation thereof and pharmaceutical composition containing the same | EGIS GYOGYSZERGYAR RT. (HU) | 2005-02-24 | — | — | US | disclosed |
| EP-1430034-B1 | SUBSTITUTED ALKYLAMINOPYRIDAZINONE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | EGYT GYOGYSZERVEGYESZETI GYAR (HU) | 2005-02-09 | — | — | EP | disclosed |
| EP-1430034-A1 | SUBSTITUTED ALKYLAMINOPYRIDAZINONE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | Egis Gyogyszergyar Rt. (HU) | 2004-06-23 | — | — | EP | disclosed |
| WO-2003027078-A1 | SUBSTITUTED ALKYLAMINOPYRIDAZINONE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | EGIS Gyógyszergyár Rt. (HU) | 2003-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043314-A1 | Substituted alkylaminopyridazinone derivatives, process for the preparation thereof and pharmaceutical composition containing the same | CYP2C19, CYP2D6, CYP3A5 | HTR1A 64/4885ADRA1A 19/4885ADRA1D 5/4885 |
| US-20060211703-A1 | Substituted alkyl-pyridazinones for the treatment of memory and learning malfunctions | CHRM1, CHRM2, CHRM5 | HTR1A 225/4885ADRA1A 217/4885ADRA1D 274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.